Fingerprint
Dive into the research topics of 'Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically